All Stories

  1. Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort study

    Article • October 2025, Springer Science + Business Media

    Marin Jukic

  2. Pharmacotherapy: Advances in overcoming therapy based on trial-and-error

    Article • January 2025, Centre for Evaluation in Education and Science (CEON/CEES)

    Marin Jukic

  3. Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials

    Article • European Neuropsychopharmacology, April 2024, Elsevier

    Marin Jukic

  4. Social isolation during adolescence causes increased generalised anxiety-like behaviour in male rats and increased sociability in male and female rats

    Article • Neuroscience Applied, January 2024, Elsevier

    Marin Jukic

  5. What is the Current Clinical Impact of the CYP2CTG Haplotype?

    Article • Clinical Pharmacology & Therapeutics, November 2023, Wiley

    Marin Jukic

  6. The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia

    Article • Neuropathology and Applied Neurobiology, January 2023, Wiley

    Marin Jukic

  7. Pharmacogenomics in treatment of depression and psychosis: an update

    Article • Trends in Pharmacological Sciences, December 2022, Elsevier

    Marin Jukic

  8. Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits

    Article • Clinical and Translational Science, October 2022, Wiley

    Marin Jukic

  9. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population

    Article • Clinical and Translational Science, June 2022, Wiley

    Marin Jukic

  10. Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching

    Article • Journal of Clinical Psychopharmacology, June 2022, Wolters Kluwer Health

    Marin Jukic

  11. CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability

    Article • Psychiatry Research, June 2022, Elsevier

    Marin Jukic

  12. Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids

    Article • Cells, May 2022, MDPI AG

    Akos Vegvari, Marin Jukic

  13. The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients

    Article • Clinical Pharmacology & Therapeutics, March 2022, Wiley

    Marin Jukic

  14. Humanized CYP2C19 transgenic mouse as an animal model of cerebellar ataxia

    Article • January 2022, Cold Spring Harbor Laboratory Press

    Marin Jukic

  15. Patients' and psychiatrists' stance on the current state of pharmacological depression treatment in Serbia and prospects of introduction of personalized pharmacotherapy and its potential effects

    Article • Arhiv za farmaciju, January 2022, Centre for Evaluation in Education and Science (CEON/CEES)

    Marin Jukic

  16. Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy

    Article • Psychoneuroendocrinology, July 2021, Elsevier

    Marin Jukic

  17. Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates

    Article • Clinical Pharmacology & Therapeutics, May 2021, Wiley

    Marin Jukic

  18. CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry

    Article • Frontiers in Pharmacology, April 2021, Frontiers

    Marin Jukic

  19. A Novel CYP2C‐Haplotype Associated With Ultrarapid Metabolism of Escitalopram

    Article • Clinical Pharmacology & Therapeutics, April 2021, Wiley

    Marin Jukic

  20. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure

    Article • JAMA Psychiatry, March 2021, American Medical Association (AMA)

    Marin Jukic

  21. Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders

    Article • Schizophrenia Research, February 2021, Elsevier

    Marin Jukic

  22. Long-Term Effects of Maternal Deprivation on the Volume of Dopaminergic Nuclei and Number of Dopaminergic Neurons in Substantia Nigra and Ventral Tegmental Area in Rats

    Article • Frontiers in Neuroanatomy, October 2020, Frontiers

    Marin Jukic

  23. Can Gi1 biased 5-HT2A inverse agonists improve the treatment of psychosis?

    Article • European Neuropsychopharmacology, August 2020, Elsevier

    Marin Jukic

  24. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs – A study based on blood sample analyses from 24,239 patients

    Article • European Neuropsychopharmacology, August 2020, Elsevier

    Marin Jukic

  25. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

    Article • Frontiers in Psychiatry, March 2020, Frontiers

    Marin Jukic

  26. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients

    Article • Neuropsychopharmacology, October 2019, Springer Science + Business Media

    Marin Jukic

  27. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study

    Article • The Lancet Psychiatry, May 2019, Elsevier

    Marin Jukic

  28. Significantly lower CYP2D6 metabolism measured as the O/N ‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 : a st...

    Article • British Journal of Clinical Pharmacology, November 2018, Wiley

    Marin Jukic

  29. Association between soft neurological signs and antioxidant enzyme activity in schizophrenic patients

    Article • Psychiatry Research, September 2018, Elsevier

    Marin Jukic

  30. Functional characterization of CYP2D7 gene variants

    Article • Pharmacogenomics, July 2018, Future Medicine

    Marin Jukic

  31. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients

    Article • American Journal of Psychiatry, May 2018, American Psychiatric Association

    Marin Jukic

  32. BMP/SMAD Pathway Promotes Neurogenesis of Midbrain Dopaminergic NeuronsIn Vivoand in Human Induced Pluripotent and Neural Stem Cells

    Article • Journal of Neuroscience, January 2018, Society for Neuroscience

    Marin Jukic

  33. Dusp16 Deficiency Causes Congenital Obstructive Hydrocephalus and Brain Overgrowth by Expansion of the Neural Progenitor Pool

    Article • Frontiers in Molecular Neuroscience, November 2017, Frontiers

    Marin Jukic

  34. Erratum: Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

    Article • Molecular Psychiatry, April 2017, Springer Science + Business Media

    Marin Jukic

  35. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

    Article • Molecular Psychiatry, November 2016, Springer Science + Business Media

    Marin Jukic

  36. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant

    Article • Drug Development Research, August 2016, Wiley

    Marin Jukic

  37. Are adult neurogenesis and glucocorticoid signaling missing links between stress and depression?

    Article • Arhiv za farmaciju, January 2016, Centre for Evaluation in Education and Science (CEON/CEES)

    Marin Jukic

  38. Otx2 Requires Lmx1b to Control the Development of Mesodiencephalic Dopaminergic Neurons

    Article • PLOS One, October 2015, PLOS

    Marin Jukic

  39. Deciphering the spatio-temporal expression and stress regulation of Fam107B, the paralog of the resilience-promoting protein DRR1 in the mouse brain

    Article • Neuroscience, April 2015, Elsevier

    Marin Jukic

  40. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates

    Article • Pharmacogenomics, November 2014, Future Medicine

    Marin Jukic

  41. Abnormal Development of Monoaminergic Neurons Is Implicated in Mood Fluctuations and Bipolar Disorder

    Article • Neuropsychopharmacology, September 2014, Nature

    Marin Jukic